AUTHORS
Sukul Khanna, Hema Hotchandani, MBBS2, Rishit Gupta3, Priyanshi Maurya, MBBS4, Varshini Srinivasan, MBBS5, Vishnu Sudhakaran, MD6, Ujjwal Soni, Internal Medicine Resident7
AFFILIATIONS
1 University of Missouri - Kansas City (UMKC) School of Medicine, KANSAS CITY, United States
2 SUNY Upstate Medical University, Syracuse, United States
3 University College of Medical Sciences, New Delhi, New Delhi, India
4 University of Missouri - Kansas City (UMKC) School of Medicine, KANSAS CITY, United States
5 University of Missouri - Kansas City (UMKC) School of Medicine, KANSAS CITY, United States
6 University of Missouri - Kansas City (UMKC) School of Medicine, KANSAS CITY, United States
7 University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
ABSTRACT
Introduction: Venetoclax plus a hypomethylating agent (HMA) is standard first-line therapy for adults with acute myeloid leukemia (AML) unfit for intensive chemotherapy. This population is old and comorbid from a cardiovascular viewpoint, yet VIALE-A excluded patients with significant cardiac disease, and the cardiovascular (CV) consequences of adding venetoclax to HMA in routine practice are undefined. We compared cardiovascular and bleeding events between venetoclax + HMA versus HMA alone.
Methods: We performed a retrospective propensity-matched cohort study in the TriNetX Global Collaborative Network (180 healthcare organizations). Adults aged 18 years or older with AML (ICD-10 C92.0, C92.00-C92.02, C92.5, C92.6, C92.A) recorded between January 2019 and July 2026 were eligible; acute promyelocytic leukemia and any prior cytarabine, daunorubicin, or idarubicin were excluded. Cohort 1 received venetoclax with azacitidine or decitabine within 1 month before or after venetoclax and cohort 2 received azacitidine or decitabine with no venetoclax exposure. Index was the first qualifying regimen. Cohorts were matched 1:1 on age, sex, ethnicity, hypertension, ischemic heart disease, cerebrovascular disease, heart failure (HF), atrial fibrillation or flutter (AF), chronic kidney disease, diabetes, obesity, hyperlipidemia, myelodysplastic syndrome (MDS), anticoagulants, antiplatelets, beta-blockers, ACE inhibitors, statins, and pre-index creatinine, hemoglobin, platelets, and lymphocyte percentage. Outcomes over days 1-180, 1-365, and 1-1095 were a composite CV endpoint (myocardial infarction, ischemic stroke, HF, cardiac arrest); AF; HF; and bleeding (gastrointestinal hemorrhage, acute posthemorrhagic anemia, intracranial hemorrhage). Risk ratios (RR) and Kaplan-Meier hazard ratios (HR) with 95% confidence intervals were calculated.
Results: 7,483 venetoclax + HMA and 3,571 HMA patients were identified; 3,203 per arm matched for the 180- and 365-day windows and 3,195 per arm for the 1095-day window. Matched cohorts were balanced (all categorical standardized differences <0.03) with a mean age of 69.7 vs 69.8 years, 59% male, hypertensive 56%, ischemic heart disease 27%, MDS 48%, HF 18%, AF 17%, ad 52% using anticoagulants. Cardiovascular outcomes did not differ at any horizon. At 180 days, composite CV events occurred in 23.3% vs 21.6% (RR 1.08, 0.98-1.18), AF in 18.5% vs 17.3% (RR 1.07, 0.96-1.19), HF in 18.3% vs 16.8% (RR 1.09, 0.98-1.22), and bleeding events in 9.7% vs 9.5% (RR 1.02, 0.88-1.19). At 365 days, values were 27.0% vs 25.4% (RR 1.06, 0.98-1.15), 20.6% vs 19.9% (RR 1.04, 0.94-1.14), 20.9% vs 19.5% (RR 1.07, 0.97-1.18), and 12.5% vs 12.5% (RR 1.00, 0.88-1.14). At 1095 days, values were 29.3% vs 29.3% (RR 1.00, 0.93-1.08), 21.9% vs 22.2% (RR 0.99, 0.90-1.08), 21.9% vs 22.4% (RR 0.98, 0.89-1.07), and 14.0% vs 15.7% (RR 0.89, 0.79-1.00).
Conclusions: In a large matched real-world cohort, adding venetoclax to HMA was not associated with excess cardiovascular events, atrial fibrillation, heart failure, or bleeding through 3 years, supporting cardiovascular tolerability in an older, comorbid population which is usually under-represented in registration trials. Prospective studies and disease-specific registries incorporating molecular risk stratification and baseline cardiovascular profiling will be needed to understand the true incremental benefit of adding venetoclax.
DISCLOSURES
Sukul Khanna: No relevant conflicts of interest to declare.